Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Licenses Leukemia Marker to Quest Diagnostics

NEW YORK (GenomeWeb News) – Trovagene today said it has licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia.

The San Diego-based molecular diagnostics firm holds the exclusive worldwide rights to an issued US patent, as well as patent applications in the US and elsewhere, covering NPM. It has licensed non-exclusive rights to the marker to several diagnostic and lab testing firms.

Under the agreement with Quest, Trovagene will receive upfront fees and royalty payments on an annual basis. Additional terms of the agreement were not disclosed.

"Physicians need accurate tools to assess prognosis, select therapies, and evaluate for bone marrow transplant," Trovagene Chief Technology Officer Charlie Rodi said in a statement. "Use of this marker can help physicians more effectively treat patients with AML."

Trovagene noted that many AMl patients have mutations in the NPM1 gene and testing for NPM1 mutations has been recommended by the National Comprehensive Cancer Network.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.